Johnson & Johnson's Lupus Drug Nipocalimab Meets Primary Endpoint in Phase 2 Trial
Johnson & Johnson announced that its experimental drug nipocalimab met the primary endpoint of a Phase 2 trial for treating moderate-to-severe systemic lupus erythematosus. The treatment reduced disease activity at 24 weeks and maintained benefits through one year.
Tickers: $JNJ
Topics: drug development pharmaceuticals systemic lupus erythematosus (SLE)